The Molecular Oncology group at CIBBIM-Nanomedicine/VHIR, led by Dr. Diego Arango, will receive 202,710 euros from the Association for International Cancer Research to continue the studies of the role of Myosin gene in colorectal cancer progression.The research is starting this month and will last until 2015. Scientists will use in vitro models and animal models, and will carry out a screening of large human tumor collections at Vall d’Hebron Hospital. The aim is to investigate Myosin as a tumor suppressor of MYO5B.This project continues "http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&mv1=5&mv2=1&mh1=0&mh2=0&mh3=0&mh4=0&ms=0&any=2012&num=3" the studies done at VHIR and published at "http://onlinelibrary.wiley.com/doi/10.1002/ijc.27856/abstract" Proceedings of the National Academy of Sciences and "http://onlinelibrary.wiley.com/doi/10.1002/ijc.27856/abstract" International Journal of Cancer, in which was proved that the loss of structural genes such as Myosin can contribute in a significant way to the progression of this type of tumors. In fact, it was demonstrated that patients with low Myosin levels were significantly associated with shorter disease-free and overall survival (less than one year), meanwhile patients with high levels of this gen in their tumors had longer life expectancy (more than 9 years).